Haleon plc (NYSE:HLN) Short Interest Update

Haleon plc (NYSE:HLN) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 18,140,000 shares, a growth of 6.8% from the December 15th total of 16,990,000 shares. Based on an average daily volume of 6,580,000 shares, the days-to-cover ratio is currently 2.8 days. Approximately 0.4% of the company’s stock are short sold.

Haleon Trading Up 0.5 %

Shares of Haleon stock opened at $9.24 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a fifty day simple moving average of $9.54 and a 200 day simple moving average of $9.72. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a market capitalization of $41.80 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.29.

Institutional Trading of Haleon

Institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its stake in shares of Haleon by 13.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company’s stock worth $8,114,000 after purchasing an additional 99,666 shares during the period. Atomi Financial Group Inc. lifted its holdings in shares of Haleon by 50.4% in the fourth quarter. Atomi Financial Group Inc. now owns 33,875 shares of the company’s stock worth $323,000 after buying an additional 11,357 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Haleon by 3.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 499,430 shares of the company’s stock valued at $4,764,000 after purchasing an additional 18,670 shares during the period. Ballentine Partners LLC boosted its stake in Haleon by 18.1% during the fourth quarter. Ballentine Partners LLC now owns 26,961 shares of the company’s stock valued at $257,000 after buying an additional 4,130 shares during the period. Finally, Clarius Group LLC purchased a new position in shares of Haleon during the fourth quarter worth about $558,000. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on HLN shares. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.